RTW Venture Fund Limited Announcement of Share Issuance (9137L)
January 15 2021 - 9:39AM
UK Regulatory
TIDMRTW
RNS Number : 9137L
RTW Venture Fund Limited
15 January 2021
LEI: 549300Q7EXQQH6KF7Z84
15 January 2021
RTW Venture Fund Limited
(the "Company")
Announcement of Share Issuance
Further to publication of the Company's 31 December 2020 net
asset value, released on 15 January 2021, and taking into
consideration interim performance of the Company's portfolio in
January 2021, the Company confirms that it may issue new ordinary
shares at a price of US$2.12 per new ordinary share, reflecting an
8.2 per cent. premium to the 31 December 2020 net asset value.
The Company intends to issue new ordinary shares on this basis
until 19 January 2021. Investors wishing to participate in this
issuance should reflect their interest to
james.e.bouverat@jpmorgan.com and carrie.fox@jpmorgan.com at J.P.
Morgan Cazenove.
For Further Enquiries
RTW Investments, LP +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations
Julia Enright, Business Development Associate
J.P. Morgan Cazenove +44 (0)20 7742 4000
William Simmonds
Jeremie Birnbaum (Corporate Finance)
James Bouverat (Sales)
Carrie Fox
Ocorian (Company Secretary) +44 (0)1481 742 642
Kevin Smith
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund
focused on identifying transformative assets with high growth
potential across the biopharmaceutical and medical technology
sectors. Driven by a long-term approach to support innovative
businesses, RTW Venture Fund invests in companies developing
next-generation therapies and technologies that can significantly
improve patients' lives.
RTW Venture Fund Limited is managed by RTW Investments, LP, a
leading healthcare investment firm with deep scientific expertise
and a strong track record of supporting companies developing
life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more
information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEBAMATMTJBBPB
(END) Dow Jones Newswires
January 15, 2021 10:39 ET (15:39 GMT)
Rtw Biotech Opportunities (LSE:RTW)
Historical Stock Chart
From Apr 2024 to May 2024
Rtw Biotech Opportunities (LSE:RTW)
Historical Stock Chart
From May 2023 to May 2024